Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Mark McDonough, Judd Jessup

Premium

Mark McDonough will become CEO of CombiMatrix when Judd Jessup retires on March 15, the molecular diagnostics firm said last week. McDonough is currently the chief commercial officer at CombiMatrix. Before joining the firm last year, he was vice president of sales, customer service, and training at Pathwork Diagnostics, another molecular diagnostics firm that specializes in microarray-based tests.

CombiMatrix appointed Jessup CEO in 2010. In recent years, he has refocused the company on prenatal and pediatric microarray-based cytogenetic testing. In a statement, Jessup portrayed his role at CombiMatrix as leading its transition to a "pure-play diagnostics lab." Calling that transition complete, he said that the company will be in "very capable hands" under McDonough's leadership.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.